Samsung Biologics Expands Collaboration with LigaChem Biosciences to Develop ADC By Investing.com

• Samsung (KS:) Biologics to ADC offer services in a new purpose-built facility
• Expanded cooperation reflects a successful partnership and expertise

INCHEON, South Korea, January 8, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced extend cooperation with LigaChem Biosciences (: 141080) do provide antibodies– drug conjugate services (ADC).

Samsung Biological drugs will support a number of LigaChem Biosciences ADCs programs on Samsung Biologics’ new dedicated ADC drive. The two companies are already collaborating on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a biotechnology pioneer in the research and development of ADC candidates.

“The latest cooperation will be further strengthened Samsung Biologics’ capabilities at all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapy to patients,” he said John Romechief executive officer and president Samsung Biologics. “We look forward to supporting our clients’ innovative ADC pipelines, ensuring the highest quality and deadlines.“

“This collaboration with Samsung Biologics will be an important step towards strengthening the supply chain of high-quality ADC drugs and increasing the competitiveness of both companies in the global ADC market, he said Yong-Zu Kimpresident and chief executive officer of LCB. “With leverage Samsung Biologics’ With our extensive experience as a CDMO, we will accelerate the development of our pipeline and rapidly bring innovative ADC treatments to patients.”

Samsung Biologics’ The ADC facility is a separate suite, equipped with a 500-liter reactor, which supports the development and production of ADC therapies. Building on the company’s experience of expertise in large-scale antibody production and process engineering, Samsung Biologics’ ADC’s range of services spans late discovery to development and conjugateson.

Samsung Biologics also actively invests through Samsung life (KS:) Science Fund in biotech companies pioneering ADC linker technologies, tools and protein engineering.

For more information, visit: https://samsungbiologics.com/services/adc

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic filling/finishing as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large to meet diverse client needs. Maximizing operational efficiency and expanding our capabilities in response to growing demand for biomanufacturing, Samsung Biologics offers a total capacity of 604 kL in Bio Campus I. The company launched Bio Campus II with the construction of plant 5, which will be operational in April 2025, adding 180 kL of bioproduction capacity. In addition, Samsung Biologics America allows the company to work in close proximity to clients based in the OUR and Europe. We continue to build our capabilities to meet our customers by investing in a dedicated ADC facility, mRNA technologies and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to the timely and complete delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence and proven expertise.

About LigaChem Biosciences

LigaChem Biosciences, Inc. (LCB) is a clinical biopharmaceutical company dedicated to the discovery and development of innovative medicines using medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with unmet medical needs. LCB advances viable pipelines in therapeutic areas within antibiotics, antifibrotics, oncology and ADC platform technologies. For more information, visit https://ligachembio.com/

Contact Samsung Biologics
Claire Kimleader Global marketing communications
cair.kim@samsung.com

LigaChem Biosciences Contact
Daeyoung JeongHead of Investor Relations/Business Development
jdy@ligachembio.com